Last Week's Biggest Stock Movers

Plenty of stocks go up and down in any given week. The gainers inspire us to keep investing. The decliners keep greed in check while reminding us about the risks of the equity markets.

Let's go over some of last week's best and worst performers.

Bellerophon Therapeutics (BLPH) -- Up 59 percent last week

The market's biggest gainer last week was once again a biotech company. Bellerophon took top honors after a study showed encouraging results for its pulmonary arterial hypertension treatment. The mid-stage clinical trials were effective for treating patients with high blood pressure.

Coca-Cola Bottling (COKE) -- Up 14 percent last week

%VIRTUAL-WSSCourseInline-1023%Things got fizzy for Coca-Cola's (KO) largest independent bottler after it spearheaded a consolidation plan. Coca-Cola Bottling struck a deal with Coca-Cola to purchase a few manufacturing facilities as well as some franchise distribution territories that it didn't already own.

The new supply system will streamline domestic operations, and the market clearly likes what that means for Coca-Cola Bottling. It was also a good week for shares of Coca-Cola itself, but the world's leading beverage company saw its stock only move 2 percent higher on the week.

Jabil Circuit (JBL) -- Up 11 percent last week

Shares of the electronics manufacturer got charged up after it posted encouraging preliminary quarterly results. Jabil posted better-than-expected financials, and it also boosted its guidance for the current quarter.

Jabil's strong report bodes well for Apple's (AAPL) iPhone 6s. Jabil is a contract manufacturer for Apple components and its encouraging outlook suggests that Apple is ramping up its production.

Sientra (SIEN) -- Down 50 percent last week

Investing in Sientra proved to be a bust last week after the maker of breast implants and breast tissue expanders was derailed overseas. The U.K.'s Medicines and Healthcare Products Regulatory Agency suspended certification of its Silimed-branded products in Europe.

Sientra sent a letter to its plastic surgeon clients, explaining that the move has no bearing on its stateside operations. Its products remain regulated and approved by the Food and Drug Administration, but investors clearly feel that the negative knock overseas could hurt sales closer to home.

Pier 1 Imports (PIR) -- Down 23 percent last week

Shares of Pier 1 shed nearly a quarter of their value after the home furnishings retailer posted disappointing quarterly results. Sales rose a mere 3 percent since the prior year, and most of that growth has come from its online retail initiatives. Store activities -- a combination of in-store sales and online orders either placed or picked up at the store -- clocked in flat.

Pier 1 also saw margins contract as it ramped up promotional and clearance activities to eat away at its excessive inventory of outdoor furniture. Pier 1's profit of 4 cents a share was a little more than half as much as analysts were expecting.

Caesars Entertainment (CZR) -- Down 22 percent last week

Betting against the house continues to be the smartest wager when it comes to Caesars Entertainment. The casino operator took a hit after reports surfaced claiming that the casino operator was at an impasse with its creditors.

Caesars is trying to avoid filing for bankruptcy, just as it continued to defend the bankruptcy of one of its subsidiaries. Caesars has big plans of restructuring itself into a company that includes spinning off its real estate holdings into an income-producing real estate investment trust, or REIT, but it won't get there on its own terms if it can't get creditors to play along.

Motley Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool owns and recommends Apple. The Motley Fool is short Caesars Entertainment and has the following options: long January 2016 $37 calls on Coca-Cola, short January 2016 $43 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. The Motley Fool recommends Coca-Cola. Try any of our Foolish newsletter services free for 30 days. Check out our free report on one great stock to buy for 2015 and beyond.